targets, page-2

Davidsyd, given the potential of the phase III, if it succeeds, the upside could be explosive. Other Hyact applications could drive the share price towards double digits, but probably on a 2-5 year horizon. I'm not personally going to get too excited about considering selling until past the $2 mark. That's if the phase III is successful. If it's not, then may have to take some medicine and sell at average cost or worse.